Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 4/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20596677 | 0.78 | SRC (0.41) | CNR2PTGDR2SRCHTR6IMPDH2 | |
| SCHEMBL16915921 | 0.77 | CNR2 (0.34) | CNR2PTGDR2 | |
| SCHEMBL18223168 | 0.75 | KDM4E (0.41) | CNR2CA1CA2SRCIMPDH2 | |
| SCHEMBL26913051 | 0.74 | DCTPP1 (0.37) | PTGDR2GAASRCHTR6 | |
| SCHEMBL15635129 | 0.69 | PTGDR2 (0.64) | PTGDR2HTR6 | |
| SCHEMBL28826513 | 0.69 | HSD11B1 (0.40) | PTGDR2CA1CA2GAAHTR6 | |
| SCHEMBL2110900 | 0.69 | HTR6 (0.44) | CNR2SRCHTR6 | |
| SCHEMBL6039628 | 0.68 | HTR6 (0.40) | CNR2CA1CA2HTR6 | |
| SCHEMBL15598377 | 0.68 | CA1 (0.46) | CA1CA2GAAHTR6 | |
| SCHEMBL16796191 | 0.68 | CNR2 (0.43) | CNR2SRCHTR6IMPDH2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3097092-B1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| US-9828363-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828363-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828363-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3097092-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | Cleave Biosciences, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160332990-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160332990-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160332990-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| WO-2015109285-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | WDR77, POP1, PSMG3 | CNR2 4081/4885PTGDR2 3633/4885CA1 4782/4885 |
| US-20160332990-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | WDR77, POP1, PSMG3 | CNR2 4081/4885PTGDR2 3633/4885CA1 4782/4885 |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | WDR77, POP1, PSMG3 | CNR2 4065/4885PTGDR2 3647/4885CA1 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.